Tag - SBBP

Markets

HCW cuts Strongbridge Biopharma PT to $10 from $18

H.C. Wainwright reduced its price target for Strongbridge Biopharma (NASDAQ:SBBP) to $10 from $18, citing an analysis of the changing dynamics of the Cushing’s syndrome landscape because of competitor programs. The...

October 30, 2020

Developments

Strongbridge Biopharma reports positive topline data from Phase 3 Cushing’s syndrome trial

Strongbridge Biopharma (NASDAQ:SBBP) reported topline data from its Phase 3 LOGICS trial evaluating RECORLEV for the treatment of endogenous Cushing’s syndrome. The study enrolled 44 patients to supplement the long-term...

September 8, 2020

Executive Moves

Strongbridge Biopharma names John Johnson as CEO

John Johnson Strongbridge Biopharma (NASDAQ:SBBP) appointed its executive chairman, John Johnson, as the company’s CEO, effective immediately. Mr. Johnson served as Strongbridge’s chairman since March 2015. In...

July 7, 2020

Developments

Strongbridge Biopharma completes enrollment in Phase 3 Cushing’s syndrome trial

Strongbridge Biopharma (NASDAQ:SBBP) completed enrollment in its Phase 3 trial of RECORLEV for the treatment of endogenous Cushing’s syndrome, an endocrine disease caused by chronic elevated cortisol exposure. A...

May 11, 2020

Executive Moves

Strongbridge Biopharma reports key leadership appointments

Richard Kollender Strongbridge Biopharma (NASDAQ:SBBP) named Richard Kollender as COO, promoted Robert Lutz to CFO and appointed David Gill to its board, effective Sept. 3. “Continuing to assemble an experienced, multi...

August 14, 2019